{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040802","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.944374+00:00","generated_at":"2026-06-08T04:19:23.846861+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Imunon Q3 net loss $3.5M; OVATION 2 shows 33% PFS improvement, OS benefit","bullets":["Net loss of $3.5M ($0.37 per share) vs $6.1M loss in Q3 2022; operating expenses down 38% to $3.9M.","Cash and equivalents $19.5M as of Sept 30, 2023; expects $1.8M from NJ NOL sales.","Interim OVATION 2 data: PFS improved ~33% in treatment arm; OS improved ~9 months; median PFS 23.7 months with PARP inhibitor combo vs 15.7 months control.","Enrolled first patient in Phase 1/2 trial of IMNN-001 + bevacizumab at MD Anderson; IND filing for IMNN-101 COVID booster on track for Q1 2024.","Entered CRADA with NIAID for Lassa virus vaccine evaluation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040802","json":"https://secwatch.observer/filing/0001493152-23-040802.json","markdown":"https://secwatch.observer/filing/0001493152-23-040802.md","text":"https://secwatch.observer/filing/0001493152-23-040802.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315223040802/0001493152-23-040802-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315223040802/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:19:23.846861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06a41a8e1abed0a38a9f843b37e4632a34497504","claim":"Imunon, Inc. reported financial results for the three and nine months ended September 30, 2023.","evidence_excerpt":"On November 14, 2023, Imunon, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223040802/0001493152-23-040802-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}